USP: Senate Language Could Disrupt Public Process For Biologic Naming

August 18, 2016 at 3:34 PM
The U.S. Pharmacopeial Convention, biosimilar makers, payers and pharmacists are concerned the Senate health committee's plan to exempt biologics from compendial standards would clear the way for FDA to take sole responsibility for establishing nonproprietary names for these products and avoid a public process. A USP spokesperson told Inside Health Policy that the measure, tucked into the committee's health innovation package, would preempt stakeholder dialogue on nonproprietary naming solutions for biologics. USP, along with several groups such as The...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.